A Phase I Trial With Cohort Expansion of BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Alpelisib (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 13 Oct 2017 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
- 23 May 2017 Planned End Date changed from 1 Jul 2017 to 1 Apr 2018.
- 09 Dec 2016 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.